Furosemide in preterm infants treated with indomethacin for patent ductus arteriosus

Objective: To evaluate the effect of furosemide on renal function and water balance in preterm infants treated with indomethacin (3 × 0.2 mg/kg at 12‐h intervals) for symptomatic patent ductus arteriosus. Patients and Methods: We performed a retrospective multi‐centre double cohort study in preterm...

Full description

Saved in:
Bibliographic Details
Published inActa Paediatrica Vol. 98; no. 5; pp. 797 - 803
Main Authors Andriessen, Peter, Struis, Nicole C., Niemarkt, Hendrik, Oetomo, Sidarto Bambang, Tanke, Ronald B., Van Overmeire, Bart
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.05.2009
Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective: To evaluate the effect of furosemide on renal function and water balance in preterm infants treated with indomethacin (3 × 0.2 mg/kg at 12‐h intervals) for symptomatic patent ductus arteriosus. Patients and Methods: We performed a retrospective multi‐centre double cohort study in preterm infants <32 weeks of gestational age. Thirty‐two infants treated with furosemide (1 mg/kg i.v.) before each indomethacin dose (furosemide group) were matched with 32 infants with indomethacin treatment alone (control‐group). Renal effects (urine output, weight gain, serum creatinine, sodium concentration) were registered. Results: The study groups were comparable for gestational age, birth weight and day of therapy. Pretreatment differences were observed for urine output, weight and serum sodium. However, no differences were noticed in day‐to‐day urine output change or weight gain between the groups. A significant increase in serum creatinine concentration (50% vs. control, 18%; p < 0.05) and a concomitant significant decrease in serum sodium (–9 vs. control, –3 mmoL/L; p < 0.05) in the furosemide group was observed 72–96 h after starting therapy. Conclusion: Furosemide before each indomethacin dose resulted in a significant increase in serum creatinine and hyponatremia, without increasing urine output.
Bibliography:ArticleID:APA1224
ark:/67375/WNG-9GP9NHMN-1
istex:8F57D1F920AE2BF59059F5FFFD819221D7A16596
ISSN:0803-5253
1651-2227
DOI:10.1111/j.1651-2227.2009.01224.x